Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model

Biochimie

Volumn 92, Issue 11, 2010, Pages 1618-1624

  Elie, Benelita Tina ^a   Gocheva, Vasilena ^a   Shree, Tanaya ^a   Dalrymple, Stacie A ^b   Holsinger, Leslie J ^b   Joyce, Johanna A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Virobay Inc   (United States)

Author keywords

Cancer; Cysteine cathepsin; Protease; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN B; CATHEPSIN L; CATHEPSIN S; CATHEPSIN V; CYSTEINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VBY 825;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INVASION; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS ISLET CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; TUMOR REGRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL AVAILABILITY; CATHEPSINS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROCARBONS, FLUORINATED; LEUCINE; MICE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROTEASE INHIBITORS; SULFONES; TUMOR BURDEN;

EID: 78149358974     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.04.023     Document Type: Article

References (48)

1. Rowe R.G., Weiss S.J. Navigating ECM barriers at the invasive front: the cancer cell-stroma interface. Annu. Rev. Cell Dev. Biol. 2009, 25:567-595.
2. S.D. Mason, J.A. Joyce, Proteolytic Cascades in Invasion and Metastasis, Cancer Metastasis: Biologic Basis and Therapeutics. Cambridge University Press. Welsh DR, Lyden DC, Psaila B (Eds.), in press.
3. Overall C.M., Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 2006, 6:227-239.
4. Palermo C., Joyce J.A. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci. 2008, 29:22-28.
5. Ulisse S., Baldini E., Sorrenti S., D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets 2009, 9:32-71.
6. Vasiljeva O., Reinheckel T., Peters C., Turk D., Turk V., Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 2007, 13:385-401.
7. Jedeszko C., Sloane B.F. Cysteine cathepsins in human cancer. Biol. Chem. 2004, 385:1017-1027.
8. Joyce J.A., Baruch A., Chehade K., Meyer-Morse N., Giraudo E., Tsai F.Y., Greenbaum D.C., Hager J.H., Bogyo M., Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004, 5:443-453.
9. Grimm J., Kirsch D.G., Windsor S.D., Kim C.F., Santiago P.M., Ntziachristos V., Jacks T., Weissleder R. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc Natl Acad Sci U S A 2005, 102:14404-14409.
10. Vasiljeva O., Papazoglou A., Kruger A., Brodoefel H., Korovin M., Deussing J., Augustin N., Nielsen B.S., Almholt K., Bogyo M., Peters C., Reinheckel T. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 2006, 66:5242-5250.
11. Bell-McGuinn K.M., Garfall A.L., Bogyo M., Hanahan D., Joyce J.A. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 2007, 67:7378-7385.
12. Gocheva V., Zeng W., Ke D., Klimstra D., Reinheckel T., Peters C., Hanahan D., Joyce J.A. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006, 20:543-556.
13. V. Gocheva, X. Chen, C. Peters, T. Reinheckel, J.A. Joyce, Deletion of cathepsin H perturbs angiogenic switching, vascularization and the growth of tumors in a mouse model of pancreatic islet cancer, Biol. Chem., in press.
14. Wang B., Sun J., Kitamoto S., Yang M., Grubb A., Chapman H.A., Kalluri R., Shi G.P. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J. Biol. Chem. 2006, 281:6020-6029.
15. Sevenich L., Schurigt U., Sachse K., Gajda M., Werner F., Muller S., Vasiljeva O., Schwinde A., Klemm N., Deussing J., Peters C., Reinheckel T. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci U S A 2010, 107:2497-2502.
16. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6:764-775.
17. Reinheckel T., Gocheva V., Peters C., Joyce J.A. Roles of cysteine proteases in tumor progression: analysis of cysteine cathepsin knockout mice in cancer models. The Cancer Degradome- Proteases and Cancer Biology 2008, 279-302. Springer Publishing. D.R. Edwards, G. Hoer-Hansen, F. Blasi, B.F. Sloane (Eds.).
18. Yasuda Y., Kaleta J., Bromme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv. Drug Deliv. Rev. 2005, 57:973-993.
19. Turk B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 2006, 5:785-799.
20. Frizler M., Stirnberg M., Sisay M.T., Gutschow M. Development of nitrile-based peptidic inhibitors of cysteine cathepsins. Curr. Top. Med. Chem. 2010, 10:294-322.
21. Meara J.P., Rich D.H. Mechanistic studies on the inactivation of papain by epoxysuccinyl inhibitors. J. Med. Chem. 1996, 39:3357-3366.
22. Navab R., Mort J.S., Brodt P. Inhibition of carcinoma cell invasion and liver metastases formation by the cysteine proteinase inhibitor E-64. Clin. Exp. Metastasis. 1997, 15:121-129.
23. Sadaghiani A.M., Verhelst S.H., Gocheva V., Hill K., Majerova E., Stinson S., Joyce J.A., Bogyo M. Design, synthesis, and evaluation of in vivo potency and selectivity of epoxysuccinyl-based inhibitors of papain-family cysteine proteases. Chem. Biol. 2007, 14:499-511.
24. Schurigt U., Sevenich L., Vannier C., Gajda M., Schwinde A., Werner F., Stahl A., von Elverfeldt D., Becker A.K., Bogyo M., Peters C., Reinheckel T. Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model. Biol. Chem. 2008, 389:1067-1074.
25. Link J.O., Zipfel S. Advances in cathepsin S inhibitor design. Curr. Opin. Drug Discov. Devel. 2006, 9:471-482.
26. Falgueyret J.P., Black W.C., Cromlish W., Desmarais S., Lamontagne S., Mellon C., Riendeau D., Rodan S., Tawa P., Wesolowski G., Bass K.E., Venkatraman S., Percival M.D. An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells. Anal. Biochem. 2004, 335:218-227.
27. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315:115-122.
28. Lopez T., Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002, 1:339-353.
29. Inoue M., Hager J.H., Ferrara N., Gerber H.P., Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 2002, 1:193-202.
30. Cullagh Mc Regression models for ordinal data. J.R. Statist. Soc. 1980, 109-142.
31. McGrath M.E., Palmer J.T., Bromme D., Somoza J.R. Crystal structure of human cathepsin S. Protein Sci. 1998, 7:1294-1302.
32. Riese R.J., Mitchell R.N., Villadangos J.A., Shi G.P., Palmer J.T., Karp E.R., De Sanctis G.T., Ploegh H.L., Chapman H.A. Cathepsin S activity regulates antigen presentation and immunity. J. Clin. Invest. 1998, 101:2351-2363.
33. Nakagawa T.Y., Brissette W.H., Lira P.D., Griffiths R.J., Petrushova N., Stock J., McNeish J.D., Eastman S.E., Howard E.D., Clarke S.R., Rosloniec E.F., Elliott E.A., Rudensky A.Y. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999, 10:207-217.
34. Shi G.P., Villadangos J.A., Dranoff G., Small C., Gu L., Haley K.J., Riese R., Ploegh H.L., Chapman H.A. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 1999, 10:197-206.
35. Ribatti D., Nico B., Crivellato E., Roccaro A.M., Vacca A. The history of the angiogenic switch concept. Leukemia 2007, 21:44-52.
36. Gocheva V., Wang H.W., Gadea B.B., Shree T., Hunter K.E., Garfall A.L., Berman T., Joyce J.A. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010, 24:241-255.
37. Shi G.P., Sukhova G.K., Kuzuya M., Ye Q., Du J., Zhang Y., Pan J.H., Lu M.L., Cheng X.W., Iguchi A., Perrey S., Lee A.M., Chapman H.A., Libby P. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ. Res. 2003, 92:493-500.
38. Chang S.H., Kanasaki K., Gocheva V., Blum G., Harper J., Moses M.A., Shih S.C., Nagy J.A., Joyce J., Bogyo M., Kalluri R., Dvorak H.F. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009, 69:4537-4544.
39. Burden R.E., Gormley J.A., Jaquin T.J., Small D.M., Quinn D.J., Hegarty S.M., Ward C., Walker B., Johnston J.A., Olwill S.A., Scott C.J. Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin. Cancer Res. 2009, 15:6042-6051.
40. Rousselet N., Mills L., Jean D., Tellez C., Bar-Eli M., Frade R. Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res. 2004, 64:146-151.
41. Burden R.E., Snoddy P., Jefferies C.A., Walker B., Scott C.J. Inhibition of cathepsin L-like proteases by cathepsin V propeptide. Biol. Chem. 2007, 388:541-545.
42. Burden R.E., Snoddy P., Buick R.J., Johnston J.A., Walker B., Scott C.J. Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment. Mol. Cancer Ther. 2008, 7:538-547.
43. Rebbaa A., Chu F., Sudha T., Gallati C., Dier U., Dyskin E., Yalcin M., Bianchini C., Shaker O., Mousa S.A. The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor. Anticancer Res. 2009, 29:4473-4481.
44. C.J. Scott, C.C. Taggart, Biologic protease inhibitors as novel therapeutic agents, Biochimie, in press.
45. Le Gall C., Bellahcene A., Bonnelye E., Gasser J.A., Castronovo V., Green J., Zimmermann J., Clezardin P. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 2007, 67:9894-9902.
46. Le Gall C., Bonnelye E., Clezardin P. Cathepsin K inhibitors as treatment of bone metastasis. Curr. Opin. Support Palliat. Care 2008, 2:218-222.
47. Lewiecki E.M. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. IDrugs 2009, 12:799-809.
48. Bromme D., Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin. Investig. Drugs 2009, 18:585-600.